摘要
炎症性肠病(IBD)是一种病因不明的慢性、复发性肠道炎症性疾病,随着生物制剂和小分子药物(SMD)等新疗法的出现,治疗IBD的疗效已有较大改观,但仍有部分患者疗效不佳。近年来国内外对难治性IBD患者采用生物制剂和/或SMD的双靶向联合治疗策略进行了有益探索,本文就双靶向治疗的定义、疗效、安全性、合适人群等问题进行探讨。
Inflammatory bowel disease(IBD)is a chronic,recurrent inflammatory bowel disease with unknown etiology.With the emergence of new therapies such as biologics and small molecule drugs(SMDs),the therapeutic effect of IBD has improved greatly,but there are still some patients with difficulty in treatment.In recent years,dual targeted therapy,which is the combination of biologics and/or SMDs,for patients with refractory IBD has been explored at home and abroad.In this paper,we will discuss the definition,efficacy,safety and suitable population of dual targeted therapy.
作者
葛文松
Ge Wensong(Department of Gastroenterology,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)
出处
《中华消化病与影像杂志（电子版）》
2023年第2期65-67,共3页
Chinese Journal of Digestion and Medical Imageology(Electronic Edition)
基金
国家自然科学基金(81200279)。
关键词
炎症性肠病
双靶向治疗
疗效
安全性
Inflammatory bowel disease
Dual targeted therapy
Efficacy
Safety
